Scancell secures USD 25m debt facility from BlackRock to fund iSCIB1+ Phase III melanoma trial

{
  "signal_id": "d9046ed4-2b6a-8ff5-fbd8-dabb02e37ba6",
  "signal_type": "news",
  "signal_subtype": "invests_into",
  "detected_at": "2026-09-28T08:31:09+00:00",
  "company": {
    "name": "BlackRock",
    "domain": "blackrock.com"
  },
  "data": {
    "url": "https://allsci.com/news/business/scancell-blackrock-melanoma-trial-funding/",
    "title": "Scancell secures USD 25m debt facility from BlackRock to fund iSCIB1+ Phase III melanoma trial - AllSci",
    "excerpt": "UK-based Scancell Holdings plc (AIM: SCLP) has secured a loan facility of up to USD 25 million from funds and accounts managed by BlackRock to fund the registrational Phase III trial of its DNA immunotherapy iSCIB1+ in advanced melanoma. The debt facility forms part of a broader financing package of up to USD 89 million assembled alongside Scancell's planned all-share merger with Neuphoria Therapeutics Inc. (Nasdaq: NEUP), which is intended to provide the combined company with a Nasdaq listing under the ticker SCLT. The wider package includes a USD 39.1 million private placement, a USD 12 million UK placing, a retail offer of up to USD 3 million, and a minimum of USD 10 million in cash from Neuphoria at closing, with merger completion expected in late Q4 2026. The facility is structured in four tranches. Scancell intends to draw down USD 7 million following shareholder approval at an extraordinary general meeting (EGM) expected in October 2026. A further USD 8 million across additional tranches becomes available upon completion of the US listing transactions and opening of the first Phase III clinical site, with a remaining tranche drawable until 31 December 2027 subject to a minimum equity fundraising threshold. Up to USD 5 million across the first three tranches is convertible into ordinary shares at BlackRock's option, at a 30% premium to the equity fundraising price...",
    "summary": "BlackRock has provided a debt facility of up to USD 25 million to Scancell Holdings to fund a Phase III trial for its melanoma immunotherapy, iSCIB1+.",
    "planning": false,
    "image_url": "https://allsci.com/og/article/news/business/scancell-blackrock-melanoma-trial-funding.png",
    "confidence": 0.9,
    "published_at": "2026-09-28T08:31:09Z",
    "article_sentence": "UK-based Scancell Holdings plc (AIM: SCLP) has secured a loan facility of up to USD 25 million from funds and accounts managed by BlackRock to fund the registrational Phase III trial of its DNA immunotherapy iSCIB1+ in advanced melanoma.",
    "amount_normalized": 25000000,
    "financing_type_tags": [
      "debt"
    ],
    "related_company_name": "Scancell Holdings plc",
    "related_company_domain": "scancell.co.uk",
    "financing_type_normalized": "debt"
  }
}

curl https://signals.autobound.ai/v1/signals/d9046ed4-2b6a-8ff5-fbd8-dabb02e37ba6 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"blackrock.com","limit":20}'